BRAIN+ I MEDIERNE
![OlderMan-Phone-shutterstock_1877563882-1920x1080 OlderMan-Phone-shutterstock_1877563882-1920x1080](https://usercontent.one/wp/www.brain-plus.com/wp-content/uploads/2021/08/OlderMan-Phone-shutterstock_1877563882-1920x1080-1-500x500.jpg?media=1667406527)
DIGITAL MEDICINE – A GLOBAL HEALTH TREND
The digital medicine trend is the next big thing at the frontier of digitalisation and has already proven a powerful way of dealing with several important diseases, where traditional, chemical medicines have failed. Software-based treatments/therapies have become FDA-approved and several large pharma companies have joined the game. With a current compounded annual growth rate of 23,1% the market size for digital medicine is projected to hit 19,1 billion USD by 2028.
![Hands-shutterstock_1702101469-1920x1080 Hands-shutterstock_1702101469-1920x1080](https://usercontent.one/wp/www.brain-plus.com/wp-content/uploads/2021/08/Hands-shutterstock_1702101469-1920x1080-1-500x500.jpg?media=1667406527)
TREATING DEMENTIA AND ALZHEIMER’S
WITH DIGITAL MEDICINE
Dementia and Alzheimer’s are both conditions, where digital medicine has proven to have a significant impact. And with dementia on the rise globally with 50 million people currently diagnosed (a number which is expected to more than triple to 152 million people by 2050), this presents a global addressable market for digital dementia treatments of approximately 2 to 5 billion USD in 10 to 15 years from today.
![Hands-shutterstock_1702101469-1920x1080 Hands-shutterstock_1702101469-1920x1080](https://usercontent.one/wp/www.brain-plus.com/wp-content/uploads/2021/08/Hands-shutterstock_1702101469-1920x1080-1-500x500.jpg?media=1667406527)
![Stock-Phone-shutterstock_1745613248-1920x1080 Stock-Phone-shutterstock_1745613248-1920x1080](https://usercontent.one/wp/www.brain-plus.com/wp-content/uploads/2021/08/Stock-Phone-shutterstock_1745613248-1920x1080-1-e1629188522376-500x500.jpg?media=1667406527)
FURTHER ANCHORING BRAIN+ AS A MARKET LEADER
The IPO will fund further product development and advancing towards the phase 3 clinical trials needed for regulatory approval in order to attract major pharma companies for strategic partnerships, as Brain+ aims to establish themselves as global market leaders by 2031, with revenue projections in several hundred millions of USD.